for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MediGene AG

MDG1k.DE

Latest Trade

6.19EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.96

 - 

10.85

As of on the XETRA ∙ Minimum 15 minute delay

Latest Developments

Medigene Announces Positive Final 2-Year Topline Data In DC Vaccine Phase I/II Trial In AML Patients

Jan 10 (Reuters) - MEDIGENE AG <MDG1k.DE>::POSITIVE FINAL 2-YEAR TOPLINE DATA IN COMPLETED DC VACCINE PHASE I/II TRIAL IN AML PATIENTS.DC VACCINATIONS WERE WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS (SAES) RELATED TO TREATMENT.PRIMARY OUTCOME MEASURES WERE SUCCESSFULLY ACHIEVED.

Medigene 9-Month EBITDA Loss Of EUR 18.6 Mln

Nov 13 (Reuters) - MEDIGENE AG <MDG1k.DE>::9-MONTH REVENUE FROM CORE BUSINESS OF IMMUNOTHERAPIES INCREASED BY 32% TO EUR 6.2 M (9M 2018: EUR 4.7 M).9-MONTH EBITDA LOSS INCREASED AS ANTICIPATED BY 48% TO EUR 18.6 M (9M 2018: EUR 12.6 M).9M NET LOSS FOR PERIOD INCREASED AS EXPECTED BY 52% TO EUR 20.0 M (9M 2018: EUR 13.2 M).CONFIRMATION OF FINANCIAL GUIDANCE 2019.

Medigene H1 EBITDA Loss Of EUR 13.2 Mln

Aug 7 (Reuters) - MEDIGENE AG <MDG1k.DE>::H1 REVENUE FROM CORE IMMUNOTHERAPIES BUSINESS GREW BY 47% TO EUR 4.9 MILLION (6M-2018: EUR 3.4 MILLION).H1 TOTAL REVENUE INCREASED BY 33% TO EUR 5.6 MILLION(6M-2018: EUR4,253K)..H1 RESEARCH AND DEVELOPMENT EXPENSES INCREASED AS PLANNED BY 26% TO EUR 10.9 MILLION (6M-2018: EUR 8.7 MILLION).H1 EBITDA LOSS INCREASED BY 77% TO EUR 13.2 MILLION(6M-2018: EUR 7.5 MILLION).CONFIRMED FINANCIAL GUIDANCE ISSUED IN 3M-2019 QUARTERLY REPORT.

Medigene: Clinical Data From Interim Analysis Of Phase I/II Trial With DC Vaccine

June 17 (Reuters) - Medigene AG <MDG1k.DE>::INTERIM ANALYSIS FROM ONGOING PHASE I/II CLINICAL TRIAL WITH DC VACCINES IN AML PATIENTS PRESENTED AT EHA.EXCELLENT SAFETY AND TOLERABILITY PROFILE.ENCOURAGING DATA ON OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL.VERY GOOD FEASIBILITY FOR MANUFACTURE OF VACCINES FROM PATIENT-DERIVED CELLS.

Medigene: Clinical Trial Agreement For HA-1 TCR Immunotherapy MDG1021 With University Of Leiden

May 22 (Reuters) - Medigene AG <MDG1k.DE>::PTA-NEWS: MEDIGENE AG: MEDIGENE ANNOUNCES CLINICAL TRIAL AGREEMENT FOR HA-1 TCR IMMUNOTHERAPY MDG1021 WITH UNIVERSITY OF LEIDEN.CLINICAL TRIAL START SCHEDULED FOR 2020.

Medigene Q1 Net Loss Of EUR 5.7 Mln

May 14 (Reuters) - MEDIGENE AG <MDG1k.DE>::Q1 EBITDA LOSS INCREASED AS PLANNED BY 31% TO EUR 5.0 M DUE TO PROGRESS IN IMMUNOTHERAPY PROGRAMS.Q1 NET LOSS FOR PERIOD INCREASED AS PLANNED BY 36% TO EUR 5.7 M.IMPROVES ITS REVENUE GUIDANCE AND EXPECTS TO GENERATE TOTAL REVENUES OF BETWEEN EUR 10 - 11 M (PREVIOUS GUIDANCE: EUR 5.5 - 6.5 M) IN 2019.CONTINUES TO EXPECT RESEARCH AND DEVELOPMENT EXPENSES OF EUR 24 -29 M IN 2019.ALSO CONFIRMS ITS EBITDA-GUIDANCE AND CONTINUES TO EXPECT A LOSS AT EBITDA LEVEL OF EUR 23 - 28 M.

Medigene Sells Remaining Rights And Inventories Of Veregen To Aresus

April 8 (Reuters) - Medigene AG <MDG1k.DE>::MEDIGENE SELLS REMAINING RIGHTS AND INVENTORIES OF VEREGEN® TO ARESUS PHARMA.ALL EXISTING RELEVANT CONTRACTS WITH DISTRIBUTION PARTNERS AND EXTERNAL SERVICE PROVIDERS WILL BE TRANSFERRED FROM MEDIGENE TO ARESUS.COMPLETES TRANSFORMATION INTO A PURE IMMUNOTHERAPY COMPANY.MEDIGENE WILL RECEIVE UP TO APPROXIMATELY EUR 7.75 MILLION FROM ARESUS FOR REMAINING VEREGEN® RIGHTS AND ALL EXISTING API STOCK.MEDIGENE'S EBITDA WILL BE AFFECTED BY A NON-CASH EFFECTIVE LOSS BETWEEN EUR 4 AND 5 MIO.EXPECTED PAYMENTS ARE RECOGNIZED AS RECEIVABLES AND DISCOUNTED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS.MEDIGENE WILL UPDATE ITS FINANCIAL GUIDANCE WITH RESPECT TO REVENUE AND EBITDA WITH ISSUING ITS QUARTERLY STATEMENT.CLOSING OF TRANSACTION INCLUDING TRANSFER OF RIGHTS IS PLANNED FOR MID-APRIL 2019.

Medigene And Roivant Affiliate Cytovant Establish Strategic Partnership

April 4 (Reuters) - Medigene AG <MDG1k.DE>::PTA-ADHOC: MEDIGENE AG: MEDIGENE AND ROIVANT AFFILIATE CYTOVANT ESTABLISH STRATEGIC RESEARCH AND DEVELOPMENT PARTNERSHIP FOR CELLULAR THERAPIES IN ASIA.MEDIGENE WILL RECEIVE AN OVERALL UPFRONT PAYMENT OF USD 10 MILLION AS WELL AS POTENTIAL DEVELOPMENT.MEDIGENE WILL BE ELIGIBLE TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF PRODUCTS IN A LOW DOUBLE-DIGIT PERCENTAGE IN RELEVANT COUNTRIES.CYTOVANT WILL REIMBURSE ALL RESEARCH AND DEVELOPMENT COSTS INCURRED BY MEDIGENE WITHIN COLLABORATION..TO RECEIVE COMMERCIAL MILESTONE PAYMENTS WHICH IN AGGREGATE COULD TOTAL OVER USD 1 BILLION.

Medigene FY Net Loss 17.0 Mln EUR, Up 7%

March 27 (Reuters) - Medigene AG <MDG1k.DE>::NET LOSS FOR THE YEAR -17.049 MILLION EUR, UP 7%.EXPECTING TO GENERATE TOTAL REVENUE OF EUR 5.5 - 6.5 M IN 2019..PLANNED 2019 EBITDA LEVEL OF EUR 23 - 28 M (2018: EUR 16.3 M)..

Medigene FY Total Revenues Amounted To EUR 7.8 Mln In 2018

March 5 (Reuters) - Medigene AG <MDG1k.DE>::FY TOTAL REVENUES AMOUNTED TO EUR 7.8 M IN 2018 (2017: EUR 8.9 M).FY EBITDA LOSS OF EUR 16.3 M (2017: EUR 14.6 M).CASH AND CASH EQUIVALENTS (LIQUID ASSETS AND TIME DEPOSITS) AMOUNTED TO EUR 71.4 M AT END OF YEAR (2017: EUR 51.7 M).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up